Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07122102) titled 'Safety and Efficacy Evaluation of Cofrogliptin (HSK7653) and Acarbose Research Among T2DMs' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Condition:
Type 2 Diabetes
Intervention:
Drug: Cofrogliptin
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: September 1, 2025
Target Sample Size: 200
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07122102
Published by ...